Literature DB >> 7503351

The reporting sensitivities of two passive surveillance systems for vaccine adverse events.

S Rosenthal1, R Chen.   

Abstract

To evaluate reporting sensitivities for vaccine adverse events, reporting rates were estimated by dividing the number of events reported to the Monitoring System for Adverse Events Following Immunization and the Vaccine Adverse Event Reporting System in a given period by the number of doses administered or distributed during the same period. Reporting sensitivity was calculated as the ratio of the rates at which events were reported to each passive surveillance system (numerator) and occurred in controlled studies (denominator). Reporting sensitivities were generally better in the public sector than in the private sector. The significant underreporting of known outcomes, together with the nonspecific nature of most adverse event reports, highlights the limitations of passive surveillance systems in assessing the incidence of vaccine adverse events.

Mesh:

Substances:

Year:  1995        PMID: 7503351      PMCID: PMC1615747          DOI: 10.2105/ajph.85.12.1706

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  18 in total

1.  Monitoring system for adverse events following immunization.

Authors:  H C Stetler; J R Mullen; J P Brennan; J R Livengood; W A Orenstein; A R Hinman
Journal:  Vaccine       Date:  1987-09       Impact factor: 3.641

2.  Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination.

Authors:  S L Cochi; L E Edmonds; K Dyer; W L Greaves; J S Marks; E Z Rovira; S R Preblud; W A Orenstein
Journal:  Am J Epidemiol       Date:  1989-02       Impact factor: 4.897

3.  Food and Drug Administration monitoring of adverse drug reactions.

Authors:  J M Sills; L A Tanner; J B Milstien
Journal:  Am J Hosp Pharm       Date:  1986-11

4.  Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines.

Authors:  A Deforest; S S Long; H W Lischner; J A Girone; J L Clark; R Srinivasan; T G Maguire; S A Diamond; R P Schiller; E P Rothstein
Journal:  Pediatrics       Date:  1988-02       Impact factor: 7.124

Review 5.  Surveillance of the safety of simultaneous administration of vaccines. The Centers for Disease Control and Prevention experience.

Authors:  R T Chen; P Haber; J R Mullen
Journal:  Ann N Y Acad Sci       Date:  1995-05-31       Impact factor: 5.691

6.  The Vaccine Adverse Event Reporting System (VAERS).

Authors:  R T Chen; S C Rastogi; J R Mullen; S W Hayes; S L Cochi; J A Donlon; S G Wassilak
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

7.  Post-vaccination symptoms following DTP and DT vaccination.

Authors:  T M Pollock; E Miller; J Y Mortimer; G Smith
Journal:  Dev Biol Stand       Date:  1985

8.  History of convulsions and use of pertussis vaccine.

Authors:  H C Stetler; W A Orenstein; K J Bart; E W Brink; J P Brennan; A R Hinman
Journal:  J Pediatr       Date:  1985-08       Impact factor: 4.406

9.  A 7-year survey of disorders attributed to vaccination in North West Thames region.

Authors:  T M Pollock; J Morris
Journal:  Lancet       Date:  1983-04-02       Impact factor: 79.321

10.  Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome.

Authors:  A M Walker; H Jick; D R Perera; R S Thompson; T A Knauss
Journal:  Am J Public Health       Date:  1987-08       Impact factor: 9.308

View more
  28 in total

1.  Rotavirus Vaccines: Current Controversies and Future Directions.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

Review 2.  MMR vaccination and autism : what is the evidence for a causal association?

Authors:  Kreesten M Madsen; Mogens Vestergaard
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Using electronic medical records to enhance detection and reporting of vaccine adverse events.

Authors:  Virginia L Hinrichsen; Benjamin Kruskal; Megan A O'Brien; Tracy A Lieu; Richard Platt
Journal:  J Am Med Inform Assoc       Date:  2007-08-21       Impact factor: 4.497

4.  Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study.

Authors:  Christian Hoppe; Patrick Obermeier; Susann Muehlhans; Maren Alchikh; Lea Seeber; Franziska Tief; Katharina Karsch; Xi Chen; Sindy Boettcher; Sabine Diedrich; Tim Conrad; Bron Kisler; Barbara Rath
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

5.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Authors:  F Tubach; D Salmon; P Ravaud; Y Allanore; P Goupille; M Bréban; B Pallot-Prades; S Pouplin; A Sacchi; R M Chichemanian; S Bretagne; D Emilie; M Lemann; O Lortholary; O Lorthololary; X Mariette
Journal:  Arthritis Rheum       Date:  2009-07

Review 6.  The complicated task of monitoring vaccine safety.

Authors:  S S Ellenberg; R T Chen
Journal:  Public Health Rep       Date:  1997 Jan-Feb       Impact factor: 2.792

7.  Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China.

Authors:  Yu Hu; Qian Li; Luoya Lin; Enfu Chen; Yaping Chen; Xiaohua Qi
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

Review 8.  Product review on the JE vaccine IXIARO.

Authors:  Christa Firbas; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

10.  Motor palsies of cranial nerves (excluding VII) after vaccination: reports to the US Vaccine Adverse Event Reporting System.

Authors:  Emily Jane Woo; Scott K Winiecki; Alan C Ou
Journal:  Hum Vaccin Immunother       Date:  2013-11-14       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.